Actos: Effective Blood Sugar Control for Type 2 Diabetes
| Product dosage: 15mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.82 | $49.02 (0%) | 🛒 Add to cart |
| 90 | $0.72 | $73.53 $64.50 (12%) | 🛒 Add to cart |
| 120 | $0.67 | $98.04 $79.98 (18%) | 🛒 Add to cart |
| 180 | $0.62 | $147.06 $110.94 (25%) | 🛒 Add to cart |
| 240 | $0.59 | $196.08 $142.76 (27%) | 🛒 Add to cart |
| 360 | $0.57
Best per pill | $294.12 $205.54 (30%) | 🛒 Add to cart |
| Product dosage: 30mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.75 | $44.72 (0%) | 🛒 Add to cart |
| 90 | $0.66 | $67.08 $59.34 (12%) | 🛒 Add to cart |
| 120 | $0.62 | $89.44 $73.96 (17%) | 🛒 Add to cart |
| 180 | $0.56 | $134.16 $101.48 (24%) | 🛒 Add to cart |
| 270 | $0.54 | $201.24 $145.34 (28%) | 🛒 Add to cart |
| 360 | $0.52
Best per pill | $268.32 $186.62 (30%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Actos (pioglitazone hydrochloride) is a prescription medication belonging to the thiazolidinedione class, approved for the management of type 2 diabetes mellitus. It functions as an insulin sensitizer, targeting insulin resistance—a core defect in the pathophysiology of type 2 diabetes. By improving the body’s response to its own insulin, Actos helps lower elevated blood glucose levels. This medication is typically used as part of a comprehensive treatment plan that includes diet, exercise, and potentially other anti-diabetic agents. Its mechanism offers a distinct approach to glycemic control, focusing on the underlying metabolic dysfunction rather than merely stimulating insulin secretion.
Features
- Active Ingredient: Pioglitazone hydrochloride.
- Drug Class: Thiazolidinedione (TZD); peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist.
- Available Strengths: 15 mg, 30 mg, and 45 mg oral tablets.
- Administration: Oral, once daily, with or without food.
- Primary Mechanism of Action: Binds to PPAR-γ receptors in adipose tissue, muscle, and liver, increasing insulin sensitivity.
- Prescription Status: Available only by prescription from a licensed healthcare provider.
Benefits
- Improves Glycemic Control: Significantly reduces hemoglobin A1c (HbA1c), fasting, and postprandial blood glucose levels by addressing insulin resistance.
- Durable Efficacy: Provides sustained, long-term blood sugar management when used consistently as part of a treatment regimen.
- Lipid Profile Modulation: Has been shown to positively affect lipid parameters, typically increasing HDL (“good”) cholesterol and lowering triglycerides.
- Beta-Cell Preservation: By reducing insulin resistance, it may decrease the secretory demand on pancreatic beta cells, potentially helping to preserve their function over time.
- Convenient Dosing: A single daily dose regimen supports patient adherence to therapy.
- Used in Combination Therapy: Can be effectively combined with other anti-diabetic agents like metformin, sulfonylureas, or insulin for enhanced glycemic control.
Common use
Actos is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is used both as monotherapy and in combination therapy with other glucose-lowering agents, including metformin, sulfonylureas, or insulin, when the current regimen does not provide adequate glycemic control. Its use is centered on patients who exhibit significant insulin resistance. Treatment decisions should be based on the individual’s metabolic needs, comorbidities, and treatment goals as determined by their healthcare provider.
Dosage and direction
The recommended starting dose for Actos monotherapy or combination therapy is 15 mg or 30 mg administered orally once daily. The dosage may be titrated based on glycemic response, up to a maximum recommended dose of 45 mg once daily. It is crucial to note that the full therapeutic effect of any dose change may not be evident for several weeks due to its mechanism of action. The tablet should be swallowed whole and can be taken with or without food. Dosing should be individualized, and regular monitoring of blood glucose and HbA1c is necessary to determine the minimal effective dose for the patient.
Precautions
- Cardiac Failure: Actos can cause dose-related fluid retention, which may exacerbate or lead to congestive heart failure. Patients should be monitored for signs and symptoms of heart failure (e.g., excessive rapid weight gain, dyspnea, edema).
- Hepatic Effects: Although rare, drug-induced hepatotoxicity is a concern. Liver enzymes (ALT) should be checked prior to initiating therapy and periodically thereafter per clinical judgement. Therapy should not be initiated in patients with active liver disease or ALT levels >2.5X the upper limit of normal.
- Hypoglycemia: When used in combination with insulin or insulin secretagogues (e.g., sulfonylureas), the risk of hypoglycemia is increased. A lower dose of the concomitant agent may be required.
- Edema: Actos is associated with an increased incidence of edema. Use with caution in patients with pre-existing edema.
- Macular Edema: Postmarketing reports have associated TZDs with diabetic macular edema. Patients presenting with visual disturbances should undergo a prompt diabetic ophthalmological assessment.
- Fractures: Increased incidence of bone fractures, particularly in the distal upper and lower limbs, has been observed in female patients taking Actos. Consider this risk when treating patients, especially women with osteoporosis.
- Bladder Cancer: Observational studies have suggested an increased risk of bladder cancer with pioglitazone use. It should not be used in patients with active bladder cancer and should be used with caution in those with a prior history. Evaluate for hematuria.
Contraindications
Actos is contraindicated in patients with:
- Known serious hypersensitivity to pioglitazone or any other component of this product.
- Active bladder cancer.
- Moderate to severe (NYHA Class III or IV) heart failure.
Possible side effect
Common side effects may include:
- Upper respiratory tract infection
- Headache
- Sinusitis
- Myalgia (muscle pain)
- Pharyngitis
- Edema (swelling, particularly in the extremities)
- Weight gain
Serious side effects require immediate medical attention and include:
- Signs of heart failure (shortness of breath, rapid weight gain, swelling)
- Symptoms of liver problems (nausea, vomiting, abdominal pain, fatigue, anorexia, dark urine, jaundice)
- Vision changes (may indicate macular edema)
- Signs of hypoglycemia (especially when combined with other drugs) - dizziness, shakiness, sweating, confusion
- Fractures, particularly in women
- Hematuria (blood in urine)
Drug interaction
Actos has several important drug interactions:
- Strong CYP2C8 Inhibitors (e.g., gemfibrozil): Concomitant use significantly increases pioglitazone exposure. Avoid combination if possible. If must be co-administered, the Actos dose should be limited to 15 mg daily.
- CYP2C8 Inducers (e.g., rifampin): May decrease pioglitazone concentrations, potentially reducing its efficacy. Monitoring of glycemic control is recommended.
- Insulin or Insulin Secretagogues (e.g., glyburide, glipizide): Increased risk of hypoglycemia. Dose reduction of the insulin or secretagogue may be necessary.
- Oral Contraceptives: Pioglitazone may reduce the effectiveness of ethinyl estradiol and norethindrone, potentially leading to contraceptive failure. An alternative or additional method of contraception should be considered.
Missed dose
If a dose of Actos is missed, it should be taken as soon as remembered on the same day. However, if it is not remembered until the next day, the missed dose should be skipped, and the regular dosing schedule resumed. Do not take a double dose to make up for a missed one.
Overdose
Experience with overdose in humans is limited. During clinical trials, the highest administered dose was a single 120 mg dose. No serious adverse events were reported. However, based on the drug’s pharmacology, the primary risks of overdose would be expected to be an exaggeration of its known adverse effects, particularly severe hypoglycemia (if combined with other agents) and significant fluid retention leading to heart failure. In the event of a suspected overdose, supportive and symptomatic treatment should be initiated. There is no specific antidote for pioglitazone overdose. Hemodialysis is unlikely to be effective due to the drug’s high protein binding.
Storage
Store Actos tablets at room temperature between 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Keep the medication in its original container, tightly closed, and out of reach of children and pets. Protect from light and moisture. Do not store in bathrooms or near sinks. Properly discard any medication that is outdated or no longer needed.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The content has been compiled from various resources but may not be exhaustive or fully updated.
Reviews
“After struggling to get my A1c below 8% with metformin alone, my endocrinologist added Actos. Within three months, my levels were down to 6.7%. The once-daily pill is easy to remember. I did experience some minor ankle swelling, but it was manageable.” - John D., 58
“Actos was effective for my blood sugar, but I had to stop due to significant weight gain of about 15 pounds over a year. My doctor and I are now exploring other options. It works well for some, but the side effect profile was not ideal for me.” - Maria L., 62
“As part of my diabetes management plan, Actos has been a cornerstone. It provided the stable control I needed without the peaks and troughs I experienced with some other medications. Regular monitoring has shown no issues, and I’ve been on it successfully for over four years.” - Robert T., 51